Turbine’s Post

🔬 Case Study: Immunotherapy Development - A Bench-Bedside Case Study🚀 {{linkedin_mention(urn:li:person:E4AoBpjCE9|Dr Craig Davison)}} walks through a fascinating bench-to-bedside case study showcasing how cutting-edge ML tools and comprehensive data analysis are advancing the development of novel immunotherapies. View: https://lnkd.in/eb5mW7C9 Key highlights include: - Utilization of NGS and ML for novel antibody discovery - In vivo and in vitro experiments to tailor therapies to cancer types - Real-time analysis of clinical trial data to monitor therapy safety and effectiveness - Rapid identification of prognostic biomarkers, slashing months off development timelines #Immunotherapy #DrugDiscovery #PrecisionMedicine #ClinicalTrials #DataScience #MachineLearning #SonraiAnalytics #InnovationInHealthcare

On the latest episode of 'Product Led Growth Leaders', hosted by Thomas Watkins, Saurabh Jain, Executive Chairman of Opyl, discusses how our custom LLM turns vast amounts of unstructured data into structured, actionable insights, providing precise probabilities for trial success. "The next step we’re thinking about after we’re done with this is to delve into generative AI. I’ve got small cell lung cancer, I’m in stage four, here’s my therapy, here’s my mode. Build a clinical trial protocol that’s most likely to succeed based on all the other cancer trials and all other small cell cancer trials." 🎧 Tune in now: https://lnkd.in/gxCkFVbd Marketing, investor, and guest appearance enquiries: [email protected] Book a demo: https://lnkd.in/g9rJtUBm #Clinicaltrials #AI #biotech #pharmaceuticals #clinicalresearch #medicalresearch #medtech #healthtech #generativeai

Biopharma companies generate a lot of proprietary data. But as the Benchling State of Tech in Biopharma report indicates, large and small Biopharma companies struggle to successfully leverage ML solutions in their discovery pipelines. At Ensemble, we’re meeting this industry need with scalable technology that automates data mapping and integration. Our “Dark Matter” solution plugs into existing data pipelines to uncover meaningful patterns and insights across complex data sets. The result? A machine learning stack that measurably accelerates decision-making and innovation. The proof? Consider our case study focused on the open-source Kinase Cancer Inhibitor dataset. Dark Matter demonstrably boosted the performance of linear and non-linear classification algorithms in identifying top-performing inhibitors. (Link: https://buff.ly/3ZKvi3a ) Better data = Better predictions. Get in touch for a demo or to learn more. https://buff.ly/3BbNKbp #BioPharma #AIReady #DrugDiscovery #Innovation#DataScience

🌟 𝗩𝗶𝘃𝗶𝗮: 𝗟𝗲𝗮𝗱𝗲𝗿𝘀 𝗶𝗻 𝗔𝗗𝗖 𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻𝘀! 🌟 At Vivia, we specialize in preclinical and translational evaluations of Antibody-Drug Conjugates (ADCs). ✅ 𝗘𝘅𝘁𝗲𝗻𝘀𝗶𝘃𝗲 𝗘𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲: Collaborated on over 20 ADCs across various cancer types. ✅ 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝘃𝗲 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: Our assays capture pharmacological profiles in real patient samples, preserving native microenvironments. ✅ 𝗞𝗲𝘆 𝗠𝗮𝗿𝗸𝗲𝗿𝘀: Identify critical data points for target expression, selectivity, and toxicity. ✅ 𝗛𝗲𝗺𝗮𝘁𝗼𝘁𝗼𝘅𝗶𝗰𝗶𝘁𝘆 𝗔𝘀𝘀𝗮𝘆𝘀: Measure effects directly in normal bone marrow samples for better in vivo replication. Let’s connect to enhance your ADC development and drive successful clinical studies! 🔬 Schedule a meeting with our team: https://lnkd.in/g-J9xBPm 🔬 For custom assays in Hematologic Malignancies, click here: https://lnkd.in/gq4N5YRs 🔬For custom assays in Solid Tumor, visit our webpage https://lnkd.in/dC5z4jeV #ADC #CancerResearch #TranslationalMedicine #ClinicalDevelopment #Innovation #ViviaBiotech

🚀 Enhance and Refine Your Spheroid Assays with SPAchip! 🔬 At ARRAYS FOR CELL NANODEVICES, SL - A4CELL, we're pushing the boundaries of drug discovery by leveraging 3D cancer models and spheroid cultures. Our Cell-LAB services powered by #SPAchip allow for the precise monitoring of spheroid cultures, ensuring consistent, reproducible results. 💡 Whether you’re in the field of cancer research or drug development, our cutting-edge technology can help boost the confidence in your cell-assay workflows. Say goodbye to variability and hello to reliable, high-quality data! 🔗 Ready to empower your drug discovery pipeline? Let’s talk about how #SPAchip can transform your 3D models. #DrugDiscovery #3DCellModels #CancerResearch #CellAssays #SPAchip #A4cell #InnovativeTechnology #Spheroids

Provectus Therapeutics has developed a cost-effective, advanced culture plate designed for single cell culture and analysis. This platform is ideal for studying tumor heterogeneity, phenotypic plasticity, and off-target mechanisms in oncology. Visit the post below for more details! #AI #cancer #drugdevelopment #precisionmedicine

FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies. This single test interrogates over 500 genes to profile a patient's solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment. Read: https://lnkd.in/d7ZyFW-d #sciencesdelavie #biotechnologie #biotechnology #innovation #innovations #research #sciences #medicaments #research #drugresearch #laboratories #labs #chemistry #chemistry #biology #biologie #biopharma #rna #rnatherapeutics #arn #lifesciences #revolution #happy

𝐀 𝐓𝐖𝐎 𝐁𝐄𝐀𝐑 𝐂𝐀𝐏𝐈𝐓𝐀𝐋 𝐏𝐎𝐑𝐓𝐅𝐎𝐋𝐈𝐎 𝐂𝐎𝐌𝐏𝐀𝐍𝐘: 𝐒𝐀𝐍𝐀𝐕𝐈𝐀 𝐎𝐍𝐂𝐎𝐋𝐎𝐆𝐘   Founded by Server Ertem, PhD, Sanavia Oncology Inc. believes that every cancer patient deserves a cure. For many patients drug resistance limits the benefit of current therapies. So Sanavia is working to access the biology that will provide the understanding needed to develop novel immunotherapies that can safely and effectively overcome drug resistance and improve patients’ lives. Sanavia uses a proprietary platform to discover unexplored, clinically relevant, cancer-specific epitopes in different types of drug resistant tumors and to generate antibodies with atomic-level specificity to these epitopes. Sanavia’s process combines high-throughput cellular analysis, single-molecule super-resolution microscopy, 3D protein modeling, and advanced computation to take maximum advantage of complementary 𝑖𝑛 𝑣𝑖𝑣𝑜 and 𝑖𝑛 𝑠𝑖𝑙𝑖𝑐𝑜 methods. Sanavia can replicate tumor biology ex-vivo with unprecedented accuracy and discover novel therapeutic targets at scale. For more information, visit www.sanavia.bio. #Sanavia #TwoBearCapital #VentureCapital #Oncology

InnoTech Precision Medicine is developing a first-in-class molecular diagnostics platform based on our patented technology for multiomics detection of various classes of biomarkers. While scientists have discovered panels of diagnostic biomarkers for different types of cancer through machine learning algorithms, current diagnostic technologies are only single omic, detecting one class of macromolecules at a time. InnoTech Precision Medicine is developing the chemistry workflow, microfluidics cartridge, and AI-enabled medical device for the simultaneous detection of different classes of cancer biomarkers. Our flagship program targets the screening and early detection of head and neck cancer, facilitating timely treatment. We're also developing solutions for screening and diagnosis of other cancers. With our multiomics platform, we deliver rapid, accurate, and cost-effective diagnostics. #LSIUSA24, #cancerdiagnosis, #headandneckcancer

AI could change the way we think about healthcare forever, potentially saving many lives per year. What if we told you that the process is already underway? 💪 The latest advancements in artificial intelligence are making it possible to help design clinical trials to help defeat some of the hardest-to-treat diseases on earth, including cancer. Researchers and pharmaceutical companies are collaborating worldwide to harness the power of these technologies, showing that AI can help drive real-world impact. Take a moment to explore the potential impact of AI on cancer research and drug discovery and development, and how we’re helping our clients to reshape the future of cancer, in this series presented by Union for International Cancer Control (UICC), and produced for them by BBC StoryWorks Commercial Productions. You can see a snippet below, and check out the full video here. 👉 https://lnkd.in/eCf5hcXA #AIbyMcKinsey #ArtificialIntelligence #RewritingCancer